Lovenox®
Enoxaparin is a low molecular weight heparin (LMWH) used for prevention and treatment of deep vein thrombosis and acute coronary syndromes.
| Dosage Form | SC Injectable (Prefilled Syringe) |
| Strength | 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg |
| Storage | Store at 25°C. Do not freeze. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
DVT prophylaxis (hip/knee replacement, abdominal surgery); DVT treatment (with/without PE); unstable angina and NSTEMI (with aspirin).
Binds to antithrombin III, enhancing its inhibition of Factor Xa. Has a higher anti-Xa to anti-IIa ratio compared to unfractionated heparin.
Each Burrard Pharmaceuticals technology transfer package for Enoxaparin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.